공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

바이오의약품 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)

Biopharmaceuticals Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 03월 상품 코드 390811
페이지 정보 영문
가격
US $ 5,000 ₩ 5,634,000 PDF (Single User License)
US $ 5,500 ₩ 6,197,000 PDF (Team License: Up to 7 Users)
US $ 7,000 ₩ 7,887,000 PDF (Site License)
US $ 8,250 ₩ 9,296,000 PDF (Corporate License)


바이오의약품 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년) Biopharmaceuticals Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 03월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 바이오 의약품(Biopharmaceuticals) 시장을 조사했으며, 시장 개요, 종류·치료 용도·지역별 시장 동향, 시장 규모 추이와 예측, 시장 성장 촉진요인 및 저해요인, 시장 기회, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

  • 시장 정의

제2장 조사 방법

제3장 주요 요약

제4장 주요 영향요인

제5장 시장 개요

  • 현재의 시장 시나리오
  • Five Forces 분석
    • 공급업체의 협상력
    • 소비자의 협상력
    • 신규 진출기업의 위협
    • 대체 제품과 서비스의 위협
    • 업계 내 경쟁

제6장 성장 촉진요인 및 저해요인, 기회, 과제 분석

  • 시장 성장 촉진요인
  • 시장 성장 저해요인
  • 시장 기회
  • 주요 과제

제7장 시장 세분화

  • 제품 종류별
    • 단클론항체
    • 재조합 성장인자
    • 정제 단백질
    • 재조합 단백질
    • 재조합 호르몬
    • 합성 면역조절제
    • 백신
  • 치료 용도별
    • 종양
    • 염증성 감염증
    • 자가면역질환
    • 대사성질환
    • 호르몬질환
    • 질환 예방
    • 심혈관질환
    • 신경질환
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 남미
    • 중동 및 아프리카

제8장 경쟁 구도

  • 기업 인수합병(M&A) 분석
  • 합의, 협력, 제휴
  • 신제품 발매

제9장 주요 기업

  • Abbvie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lily & Co.
  • Johnson & Johnson
  • Novartis AG
  • Novo Nordisk Inc.
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Roche Holding AG
  • 기타

제10장 향후 전망

LSH 18.08.03

The global biopharmaceutical market is valued at approximately USD 325.17 billion in 2020 and is expected to witness a revenue of USD 496.71 billion in 2026, with a CAGR of 7.32% over the forecast period.

The ongoing pandemic of COVID-19 globally is expected to have a significant impact on the biopharmaceutical industry. Most of the biopharmaceutical companies are striving extensively for the development of the vaccine against the SARS-CoV2 virus. Some of the candidates are traditional-type vaccines such as inactivated and attenuated products, however, most of the vaccine candidates being developed are advanced DNA, RNA, and protein subunit vaccines. Thus, this factor is expected to boost the growth of the biopharmaceutical market over the pandemic. However, the clinical and regulatory procedures for drug candidates of other indications can witness a slow pace due to the shifting priorities of the healthcare system, to reduce the infections to clinical trial patients.

The market is largely driven by the growing geriatric population, increasing burden of chronic diseases, and rising inclination toward targeted therapy. According to the Globocan 2020 report, a total of 19,292,789 new cancer cases were diagnosed, with 9,958,133 deaths due to cancers worldwide. Additionally, as per the data from United Nations World Population Prospects 2019 report, by 2050, one in six people in the world will be over age 65, which is an increase from one in 11 in 2019 and by 2050, one in four persons living in Europe and Northern America could be aged 65 or over. The number of persons aged 80 years or over globally is projected to triple, from 143 million in 2019 to 426 million in 2050.

Also, the huge demand for biopharmaceutical is facilitated by an accelerating focus on research and related investment. The ability of biopharmaceutical products to address previously untreatable conditions has introduced innovative drugs in the market. Thus, given the aforementioned factors, the studied market is expected to bolster over the forecast period.

Also, the market demand for biopharmaceuticals is increasing with the rising desire to circumvent both the side-effects associated with some small-molecule therapeutics and invasive surgical treatments. However, stringent regulatory issues along with the requirement of high investment in the development of a biopharmaceutical drug, are the growth limiting factor for the studied market.

Key Market Trends

Monoclonal Antibodies is Expected to Hold a High Market Share During the Forecast Period

The successful use of monoclonal antibodies and antibody derivatives in therapeutics is the major driver for the rapid growth of the studied segment. The therapeutic applications of monoclonal antibodies include in the areas of cancer, rheumatoid arthritis, multiple sclerosis, cardiovascular diseases, among others.

The recent COVID-19 outbreak is creating a huge burden on healthcare systems. Researchers across the world are continuously making efforts to cope with this rising burden. Thus, the demand for monoclonal antibodies targeting COVID-19 is likely to exceed. For instance, in July 2020, an anti-CD6 IgG1 monoclonal antibody named Itolizumab (ALZUMAb), from Biocon Ltd, India has been approved by the Drugs Controller General of India(DCGI) for the emergency treatment of cytokine release syndrome in acute respiratory distress syndrome patients, infected with COVID-19.

Additionally, the growing FDA approvals and new product launches for various indications are expected to drive the segment. For instance, in Oct 2019, Novartis received FDA approval for its Beovu (brolucizumab) injection, also known as RTH258 for the treatment of wet age-related macular degeneration (AMD). Also, in March 2019, US FDA approved Pfizer's oncology biosimilar, TRAZIMERA, which is a monoclonal antibody biosimilar to the originator biologic medicine, Herceptin. Thus, owing to the aforementioned factors, the monoclonal antibody segment is anticipated to witness significant growth over the forecast period.

North America Dominates the Market and Expected to do the Same in the Forecast Period

The growing burden of chronic disease and increasing investment in research and development activities in the United States are the major factors attributing to the growth of the biopharmaceuticals market in North America. The United States has been recognized as the innovation capital of the world for life sciences, and it is involved in global capital investments in the early stages of biopharmaceutical companies.

During the present COVID-19 pandemic, almost all the biopharmaceutical companies in the region are striving for the development of effective therapeutics against COVID-19, and this is expected to boost the studied market over the pandemic in North America. According to the Pharmaceutical Research and Manufacturers of America, as of January 2021, nearly 1,750 clinical trials were in progress for the development of vaccines and drugs in the treatment of COVID-19, among which 420 clinical trials were based in the United States.

According to Globocan 2020, the estimated incidence of cancer cases in the United States accounted for 2,281,658, with 612,390 deaths in 2020. The high incidence of cancers surges the demand for effective therapeutics and thus, drives the studied market. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), in 2018, more than 4.7 million people work in the biopharmaceutical industry in the United States, across a broad spectrum of occupations, including scientific research, technical support, and manufacturing. Additionally, in March 2020, Thermo Fisher Scientific, Inc, invested nearly USD 475 million as a biopharma investment in the expansion of biologics, cell and gene therapy, and drug product development and in increasing its commercial capabilities globally. Similarly, in Jan 2020, Eli Lilly and Company entered into an agreement to acquire Dermira, a biopharmaceutical company. This acquisition aids in the expansion of the company's biopharmaceutical portfolio with the addition of Dermira's lebrikizumab, an IL-13 antibody that is intended for use in the treatment of moderate-to-severe atopic dermatitis. Thus, given the aforementioned factors, the studied market is expected to propel significantly over the forecast period in North America

Competitive Landscape

The biopharmaceuticals market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by new product launches. Companies, like Amgen Inc., Eli Lily and Company, Johnson and Johnson, Sanofi S.A., AstraZeneca plc and Pfizer Inc. hold a significant share in the biopharmaceuticals market and are involved in various strategic alliance such as acquisitions and collaborations to expand the product portfolio. For instance, in Aug 2020, Sanofi S.A. entered into a definitive agreement to acquire Principia Biopharma Inc., a late-stage biopharmaceutical company that is involved in the development of treatments for immune-mediated diseases.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Acceptance for Biopharmaceuticals
    • 4.2.2 Growing Burden of Chronic Diseases Worldwide
    • 4.2.3 Increasing R & D Investments
  • 4.3 Market Restraints
    • 4.3.1 High-end Manufacturing Requirements and Competition from Low-Cost Biosimilars
    • 4.3.2 Complicated and Cumbersome Regulatory Requirements
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Monoclonal Antibodies
      • 5.1.1.1 Anti Cancer Monoclonal Antibodies
      • 5.1.1.2 Anti-Inflammatory Monoclonal Antibodies
      • 5.1.1.3 Other Monoclonal Antibodies
    • 5.1.2 Recombinant Growth Factors
      • 5.1.2.1 Erythropoietin
      • 5.1.2.2 Granulocyte Colony Stimulating Factor
    • 5.1.3 Purified Proteins
      • 5.1.3.1 Leukemia Inhibtory Factor(LIF)
      • 5.1.3.2 P53 Protein
      • 5.1.3.3 P38 Protein
      • 5.1.3.4 Other Purified Proteins
    • 5.1.4 Recombinant Proteins
      • 5.1.4.1 Serum Albumin
      • 5.1.4.2 Amyloid Protein
      • 5.1.4.3 Defensin
      • 5.1.4.4 Transferrin
    • 5.1.5 Recombinant Hormones
      • 5.1.5.1 Recombinant Human Growth Hormones
      • 5.1.5.2 Recombinant Insulin
      • 5.1.5.3 Other Recombinant Hormones
    • 5.1.6 Vaccines
      • 5.1.6.1 Recombinant Vaccines
      • 5.1.6.1.1 Cancer Vaccines
      • 5.1.6.1.2 Malaria Vaccines
      • 5.1.6.1.3 Ebola Vaccine
      • 5.1.6.1.4 Hepatitis B Vaccine
      • 5.1.6.1.5 Tetanus Vaccine
      • 5.1.6.1.6 Diptheria Vaccine
      • 5.1.6.1.7 Cholera Vaccine
      • 5.1.6.1.8 Other Recombinant Vaccines
      • 5.1.6.2 Conventional Vaccines
      • 5.1.6.2.1 Polio Vaccine
      • 5.1.6.2.2 Pox Vaccine
      • 5.1.6.2.3 Other Conventional Vaccines
    • 5.1.7 Recombinant Enzymes
      • 5.1.7.1 Enterokinase
      • 5.1.7.2 Cyclase
      • 5.1.7.3 Caspase
      • 5.1.7.4 Cathepsin
    • 5.1.8 Cell and Gene Therapies
      • 5.1.8.1 Allogenic Products
      • 5.1.8.2 Autologous Products
      • 5.1.8.3 Acellular Products
    • 5.1.9 Synthetic Immunomodulators
      • 5.1.9.1 Cytokines, Interferons, Interleukins
    • 5.1.10 Other Product Types
      • 5.1.10.1 Blood Factors
      • 5.1.10.2 Other Product Types
  • 5.2 By Therapeutic Application
    • 5.2.1 Oncology
    • 5.2.2 Inflammatory and Infectious Diseases
    • 5.2.3 Autoimmune Disorders
    • 5.2.4 Metabolic Disorders
    • 5.2.5 Hormonal Disorders
    • 5.2.6 Cardiovascular Diseases
    • 5.2.7 Neurological Diseases
    • 5.2.8 Other Diseases
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie Inc
    • 6.1.2 Amgen Inc
    • 6.1.3 Bristol-Myers Squibb Company
    • 6.1.4 Eli Lilly and Company
    • 6.1.5 Johnson & Johnson
    • 6.1.6 Novartis AG
    • 6.1.7 Novo Nordisk A/S
    • 6.1.8 Pfizer Inc.
    • 6.1.9 GlaxoSmithKline PLC
    • 6.1.10 F. Hoffmann-La Roche AG
    • 6.1.11 Biogen, Inc.
    • 6.1.12 Merck Co & Inc.
    • 6.1.13 Sanofi S.A.
    • 6.1.14 AstraZeneca plc
    • 6.1.15 Bayer AG
    • 6.1.16 Takeda Pharmaceutical Company Limited
    • 6.1.17 Agilent Technologies, Inc.
    • 6.1.18 Thermo Fisher Scientific, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q